Chiasma Stock Forecast, Price & News

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Chiasma in the last twelve months. There are currently 2 hold ratings and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" Chiasma stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in CHMA, but not buy additional shares or sell existing shares.
View analyst ratings for Chiasma or view top-rated stocks.

Wall Street analysts have given Chiasma a "Hold" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Chiasma wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Chiasma saw a decrease in short interest during the month of June. As of June 30th, there was short interest totaling 849,900 shares, a decrease of 67.4% from the June 15th total of 2,610,000 shares. Based on an average trading volume of 2,860,000 shares, the days-to-cover ratio is presently 0.3 days. Currently, 1.7% of the company's shares are short sold.
View Chiasma's Short Interest.

Chiasma is scheduled to release its next quarterly earnings announcement on Monday, August 9th 2021.
View our earnings forecast for Chiasma.

Chiasma, Inc. (NASDAQ:CHMA) posted its quarterly earnings results on Thursday, May, 6th. The biotechnology company reported ($0.49) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.31) by $0.18. The biotechnology company had revenue of $1.92 million for the quarter, compared to analysts' expectations of $1.80 million.
View Chiasma's earnings history.

Chiasma's stock was trading at $3.92 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, CHMA shares have increased by 6.6% and is now trading at $4.18.
View which stocks have been most impacted by COVID-19.

3 Wall Street analysts have issued 12-month price objectives for Chiasma's stock. Their forecasts range from $8.00 to $15.00. On average, they anticipate Chiasma's share price to reach $11.67 in the next year. This suggests a possible upside of 179.1% from the stock's current price.
View analysts' price targets for Chiasma or view top-rated stocks among Wall Street analysts.

Some companies that are related to Chiasma include ESSA Pharma (EPIX), Rhythm Pharmaceuticals (RYTM), Kiniksa Pharmaceuticals (KNSA), Humanigen (HGEN), Olema Pharmaceuticals (OLMA), Kinnate Biopharma (KNTE), Zogenix (ZGNX), Shattuck Labs (STTK), NRx Pharmaceuticals (NRXP), Keros Therapeutics (KROS), Omeros (OMER), Pliant Therapeutics (PLRX), Theravance Biopharma (TBPH), Collegium Pharmaceutical (COLL) and Ocular Therapeutix (OCUL).
View all of CHMA's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Chiasma investors own include Arbutus Biopharma (ABUS), Bausch Health Companies (BHC), GW Pharmaceuticals (GWPH), BioDelivery Sciences International (BDSI), Sorrento Therapeutics (SRNE), SCYNEXIS (SCYX), Viking Therapeutics (VKTX), Amarin (AMRN), Exelixis (EXEL) and Ovid Therapeutics (OVID).

(CHMA) raised $76 million in an initial public offering (IPO) on Thursday, July 16th 2015. The company issued 5,400,000 shares at a price of $13.00-$15.00 per share. Barclays and Cowen and Company served as the underwriters for the IPO and William Blair and Oppenheimer & Co. were co-managers.

Chiasma trades on the NASDAQ under the ticker symbol "CHMA."

Shares of CHMA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of CHMA stock can currently be purchased for approximately $4.18.

Chiasma has a market capitalization of $242.00 million and generates $1.11 million in revenue each year. The biotechnology company earns $-74,780,000.00 in net income (profit) each year or ($1.43) on an earnings per share basis.

Chiasma employs 84 workers across the globe.

The official website for Chiasma is www.chiasmapharma.com.

Chiasma is headquartered at 140 Kendrick Street Building C East, Needham MA, 02494.

Chiasma's mailing address is 140 Kendrick Street Building C East, Needham MA, 02494. The biotechnology company can be reached via phone at 617-928-5300 or via email at [email protected]